<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072990</url>
  </required_header>
  <id_info>
    <org_study_id>2020-035-KY</org_study_id>
    <nct_id>NCT05072990</nct_id>
  </id_info>
  <brief_title>Type 2 Diabetes Mellitus With Obesity and Dyslipidemia Treated by Chinese Herbal Medicine</brief_title>
  <official_title>Type 2 Diabetes Mellitus With Obesity and Dyslipidemia Treated by Chinese Herbal Medicine: a Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a retrospective review of participants who visited Department of Endocrinology,&#xD;
      Guang'anmen Hospital and accepted traditional Chinese medicine formula for at least sis&#xD;
      months, from January 2015 to December 2020. All the participants should be diagnosed as type&#xD;
      2 diabetes mellitus, obesity and dyslipidemia. Therapeutic effect of traditional Chinese&#xD;
      medicine will be evaluated based on the changes of blood glucose, body mass index, blood&#xD;
      lipids, and blood pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnostic criteria for type 2 diabetes mellitus and obesity are based on the Guideline&#xD;
      for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). The&#xD;
      diagnostic criteria of dyslipidaemia are based on the Chinese Guidelines on Prevention and&#xD;
      Treatment of Dyslipidaemia in Adults (2016, revision edition).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline HbA1c at 3 months, 6 months</measure>
    <time_frame>0 month, 3 months, 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline Fasting Blood Glucose at 3 months, 6 months</measure>
    <time_frame>0 month, 3 months, 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline Low Density Lipoprotein at 3 months, 6 months</measure>
    <time_frame>0 month, 3 months, 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline Triglyceride at 3 months, 6 months</measure>
    <time_frame>0 month, 3 months, 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline Body Mass Index at 3 months, 6 months</measure>
    <time_frame>0 month, 3 months, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from Postprandial Blood Glucose at 6 months</measure>
    <time_frame>0 month, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Total Cholesterol at 6 months</measure>
    <time_frame>0 month, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from High Density Lipoprotein at 6 months</measure>
    <time_frame>0 month, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Systolic Blood Pressure at 6 months</measure>
    <time_frame>0 month, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Diastolic Blood Pressure at 6 months</measure>
    <time_frame>0 month, 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes Mellitus in Obese</condition>
  <condition>Dyslipidemia Associated With Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Observational group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chinese herb medicine</intervention_name>
    <description>Patients took 200 ml Chinese herb decoction twice a day before breakfast and dinner.</description>
    <arm_group_label>Observational group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who visited Department of Endocrinology, Guang'anmen Hospital, from January 2015&#xD;
        to December 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet at least three of the requirements below; 1) Fasting Plasma Glucose &gt; 6.1 mmol/L&#xD;
             or 2-hour Postprandial Blood Glucose &gt; 7.8 mmol/L or diagnosed as type 2 diabetes&#xD;
             mellitus; 2) Body Mass Index &gt; 25 kg / m2; 3) Total Cholesterol &gt; 5.2 mmol / L; Or&#xD;
             Triglyceride &gt; 1.70 mmol / L; Or Low-Density Lipoprotein &gt; 3.12 mmol / L; Or&#xD;
             High-Density Lipoprotein &lt; 1.04 mmol/L. 4) Systolic blood pressure &gt; 130 mmHg or&#xD;
             Diastolic blood pressure &gt; 85 mmHg or diagnosed as hypertension;&#xD;
&#xD;
          2. Received 6 months of continuous Chinese herbal medicine treatment;&#xD;
&#xD;
          3. During the period of receiving Chinese herbal medicine, the patients continued to take&#xD;
             western medicine according to the doctor's advice as before.&#xD;
&#xD;
          4. During the period of receiving Chinese herbal medicine, diet and exercise continued&#xD;
             according to the original routine, and the tests would be reviewed in the same&#xD;
             institution.&#xD;
&#xD;
          5. Aged 18 to 80 years at the time of their consent;&#xD;
&#xD;
          6. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who had serious heart, lung, liver, kidney and brain diseases; serious&#xD;
             infectious or hemorrhagic diseases; serious nervous system diseases, mental&#xD;
             instability; or could not cooperate with treatment were excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiaxing Tian, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiaxing Tian, PhD</last_name>
    <phone>8601088001166</phone>
    <email>tina_yai@126.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jiaxing Tian</investigator_full_name>
    <investigator_title>Attending Physician, Department of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>dyslipidemias</keyword>
  <keyword>obesity</keyword>
  <keyword>Chinese herbal medicine</keyword>
  <keyword>retrospective review</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

